Skip to content
value.today

Crossbow Therapeutics, Inc.

Total raised
$68 M
2 rounds on record
Latest round
$30 M
Sep 2025
First round on record
Mar 2023
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Crossbow Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2025$30 MNo. 2$10 to $50 million

Crossbow Therapeutics, Inc.: Raise no. 2, Sep 2025

Investors in this round

17 investors had bought by the notice of Sep 30, 2025: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $80 M offered; $50 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Nolte · Executive Officer
  • Briggs Morrison · Executive Officer, Director, Promoter
  • Dmitri Wiederschain · Executive Officer
  • Alexandra Cantley · Director
  • Alon Lazarus · Director
  • Charles Baum · Director
  • Irena Melnikova · Director
  • Sakae Asanuma · Director
  • Todd Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Briggs Morrison, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 30, 2025. Read the notice at the SEC.

equitySEC
Mar 2023$38 MNo. 1$10 to $50 million

Crossbow Therapeutics, Inc.: Raise no. 1, Mar 2023

Investors in this round

15 investors had bought by the notice of Apr 12, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $80 M offered; $42 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Briggs Morrison · Executive Officer, Director
  • Geraldine Paulus · Executive Officer
  • Alexandra Cantley · Director
  • Irena Melnikova · Director
  • Todd Foley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Briggs Morrison, Ceo. Source: SEC Form D, newest notice filed Apr 12, 2023. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Crossbow Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2025).

    SEC Form D · Sep 2025

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2025

That is all the official record says: Crossbow Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Crossbow Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Crossbow Therapeutics, Inc.
NameRoleNamed in
Alexander NolteExecutive officerSep 2025
Briggs MorrisonExecutive officerSep 2025
Dmitri WiederschainExecutive officerSep 2025
Geraldine PaulusExecutive officerApr 2023
Alexandra CantleyDirectorSep 2025
Alon LazarusDirectorSep 2025
Briggs MorrisonDirectorSep 2025
Charles BaumDirectorSep 2025
Irena MelnikovaDirectorSep 2025
Sakae AsanumaDirectorSep 2025
Todd FoleyDirectorSep 2025
Briggs MorrisonPromoterSep 2025